Verition Fund Management LLC Purchases 52,084 Shares of Savara Inc (NASDAQ:SVRA)

Verition Fund Management LLC increased its position in Savara Inc (NASDAQ:SVRA) by 83.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 114,495 shares of the company’s stock after purchasing an additional 52,084 shares during the quarter. Verition Fund Management LLC owned approximately 0.07% of Savara worth $485,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of SVRA. Choreo LLC acquired a new stake in Savara during the second quarter worth approximately $59,000. DRW Securities LLC bought a new stake in shares of Savara during the 2nd quarter valued at $62,000. Principal Financial Group Inc. raised its position in shares of Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after buying an additional 6,973 shares in the last quarter. Profund Advisors LLC acquired a new position in Savara during the second quarter valued at approximately $105,000. Finally, BNP Paribas Financial Markets boosted its position in Savara by 258.9% in the third quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock valued at $109,000 after buying an additional 18,534 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Savara news, Director Joseph S. Mccracken bought 20,000 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was purchased at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the completion of the transaction, the director now directly owns 210,837 shares of the company’s stock, valued at $621,969.15. This trade represents a 10.48 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 5.13% of the company’s stock.

Savara Stock Performance

SVRA opened at $3.49 on Thursday. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. The company’s fifty day moving average price is $3.54 and its two-hundred day moving average price is $4.03. The company has a market cap of $598.95 million, a price-to-earnings ratio of -8.12 and a beta of 0.92. Savara Inc has a 1-year low of $2.82 and a 1-year high of $5.70.

Savara (NASDAQ:SVRA) last released its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). On average, analysts expect that Savara Inc will post -0.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. HC Wainwright dropped their target price on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Savara in a research report on Tuesday, October 1st. Finally, Evercore ISI restated an “in-line” rating and set a $5.00 price target (down from $7.00) on shares of Savara in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Savara presently has an average rating of “Moderate Buy” and an average price target of $10.17.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.